StockData
Camp4 Therapeutics Corp logo

Camp4 Therapeutics Corp (CAMP) stock

CAMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3057% above fair value
$3.80−0.29 (-7.09%)

Close on Nov 13, 2026Market cap $238.46MP/E –Yield 0.00%

Camp4 Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Camp4 Therapeutics's price to sales ratio was 51.7× on Nov 11, 2026, against 46.9× a year earlier. Over the last 2 years it ranged from 0.5× to 151.7×, with a median of 46.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202651.7×−23.9
2025Dec 31, 202575.6×+61.6
2024Oct 31, 202414.0×–

More Camp4 Therapeutics figures

See a number that looks wrong?